A first-in-human, investigator sponsored clinical trial of ICTCAR014 for refractory diffuse Large B Cell Lymphoma (DLBCL)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2019 New trial record
08 May 2019 According to an Innovative Cellular Therapeutics media release, this trial is a source of human clinical proof-of-concept data for ICTCAR014, for which company intend to submit a U.S. IND for the treatment of Non-Hodgkin Lymphoma this year.
08 May 2019 According to an Innovative Cellular Therapeutics media release, data from the study was presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com